George P. Vlasuk, Phd

Biography

  George Vlasuk is a scientifically trained executive with nearly 30 years of leadership experience in drug discovery and development at small and large biotechnology and pharmaceutical companies. Before joining Navitor, Dr. Vlasuk served as Chief Executive Officer of Sirtris, a GlaxoSmithKline Company, from 2009 to 2013. Prior to Sirtris, Dr. Vlasuk was the Vice President, Metabolic Disease and Hemophilia Research, at Wyeth Pharmaceuticals. Earlier at Wyeth, Dr. Vlasuk led the areas of cardiovascular and metabolic diseases (CVMD), focusing on Type 2 diabetes, obesity, diabetic complications, heart failure, dyslipidemia/ atherosclerosis and cardiac arrhythmia. Prior to Wyeth, Dr. Vlasuk served as Chief Scientific Officer and Executive Vice President of Research and Development at the biopharmaceutical company Corvas International, from 1991 until 2003, following the merger of Corvas and Dendreon Corporation. While at Corvas, he directed research in the discovery, pre-clinical and clinical evaluations of novel anti-thrombotic, anti-inflammatory and anti-tumor agents. As a member of the senior management team and the board of directors at Corvas, Dr. Vlasuk represented Corvas in discussions with potential corporate partners, public and private investors and equity analysts.

Research Interest

Business development